Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine entities : Gritstone oncology, inc. save search
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: -6.28%
H: 1.25%
C: -13.83%
vaccine results study platform
Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio’s BARDA Award
Published: 2023-10-12 (Crawled : 23:00) - biospace.com/
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: 0.0%
H: 1.19%
C: -4.31%
covid-19 award candidate vaccine sciences technology
Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine
Published: 2023-10-11 (Crawled : 11:00) - globenewswire.com
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: 0.35%
H: 4.9%
C: -10.84%
covid-19 vaccine
Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023
Published: 2023-10-04 (Crawled : 20:00) - globenewswire.com
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: -2.45%
H: 6.9%
C: 0.84%
covid-19 candidate vaccine
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
Published: 2023-09-27 (Crawled : 20:00) - globenewswire.com
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: 21.85%
H: 11.03%
C: 7.59%
covid-19 candidate vaccine contract study
Gritstone bio Announces Publication of Interim Results from Phase 1 Study of Self-amplifying mRNA (samRNA) Vaccine Against COVID-19 in Nature Communications
Published: 2023-06-08 (Crawled : 11:00) - globenewswire.com
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: -0.42%
H: 5.04%
C: 5.04%
covid-19 vaccine mrna publication communications results study
Gritstone bio Presents Advances in Neoantigen Prediction and Cancer Vaccine Immunogenicity at the 2023 AACR Annual Meeting
Published: 2023-04-17 (Crawled : 20:00) - biospace.com/
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: 1.98%
H: 4.85%
C: -7.77%
vaccine cancer meeting
Gritstone bio Announces Presentations on Neoantigen Prediction Capabilities and Cancer Vaccine Programs at the 2023 AACR Annual Meeting
Published: 2023-03-15 (Crawled : 11:00) - globenewswire.com
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: -1.54%
H: 1.96%
C: 0.0%
meeting vaccine cancer
Gritstone bio Granted Two New U.S. Patents for Self-amplifying mRNA (samRNA)-- Patents support Gritstone’s pioneering work in the application of next-generation samRNA vaccine technology in oncology and infectious disease --
Published: 2022-12-13 (Crawled : 14:00) - biospace.com/
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: 8.91%
H: 25.27%
C: 10.68%
disease work vaccine application mrna technology granted
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors
Published: 2022-08-15 (Crawled : 23:00) - biospace.com/
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: 0.0%
H: 3.41%
C: -0.73%
vaccine study phase 1
Gritstone Announces Results from Preclinical Study of its Self-amplifying mRNA (samRNA) Vaccine Against SARS-CoV-2 Published in Nature Communications
Published: 2022-06-10 (Crawled : 13:00) - biospace.com/
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: 0.0%
preclinical communications vaccine mrna sars-cov-2 results pre-clinical
Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and Delivery
Published: 2022-04-12 (Crawled : 21:00) - globenewswire.com
BMY | $48.58 0.58% 2.6M
|
Health Technology
|
| O: 0.24%
H: 0.53%
C: 0.18%
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: 1.63%
H: 2.0%
C: 0.8%
vaccine designation
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
Published: 2022-01-13 (Crawled : 13:00) - biospace.com/
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: -6.43%
H: 1.98%
C: -3.82%
satellite treatment phase 2 rosa phase 2/3 trial cancer colorectal cancer vaccine als enroll
Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19
Published: 2022-01-04 (Crawled : 15:30) - biospace.com/
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: -1.56%
H: 0.83%
C: -41.5%
covid-19 covid cel phase 1 positive results vaccine t-cell
Gritstone bio and CEPI Expand Vaccine Agreement to Tackle Omicron Variant
Published: 2021-12-06 (Crawled : 22:00) - biospace.com/
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: -0.78%
H: 0.0%
C: 0.0%
vaccine
The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines
Published: 2021-11-29 (Crawled : 12:00) - globenewswire.com
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: 2.95%
H: 0.66%
C: -7.28%
covid vaccine sars-cov-2 t-cell
Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2
Published: 2021-11-10 (Crawled : 12:15) - globenewswire.com
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: -1.34%
H: 9.31%
C: 1.9%
covid positive vaccine preclinical sars-cov-2 pre-clinical
Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer
Published: 2021-09-20 (Crawled : 12:00) - biospace.com/
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: -22.14%
H: 10.92%
C: 8.35%
covid vaccine trial
Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program (CORAL) Against SARS-CoV-2 Variants of Concern
Published: 2021-08-17 (Crawled : 12:00) - biospace.com/
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: 0.0%
H: 11.25%
C: 8.5%
covid vaccine sars-cov-2
Gritstone Announces First Person Dosed with its Second-Generation COVID-19 Vaccine in Phase 1 Study Conducted and Supported by NIAID/IDCRC
Published: 2021-03-29 (Crawled : 19:00) - biospace.com/
GRTS | $0.7477 0.54% 600K
|
Health Technology
|
| O: 0.09%
H: 2.0%
C: -10.27%
covid phase 1 vaccine phase 3 phase 2
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
BSFC | $0.0822 27.64% 75M
|
Manufacturing
RWOD | $10.08 26.05% 5.6M
|
n/a
CHRO | $1.53 24.9% 100K
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
INSG | $2.98 23.14% 190K
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.